ARCHIMED is a leading, global private equity firm focused exclusively on healthcare industries. ARCHIMED international team combines investment, medical, scientific and operational expertise to serve as a strategic and financial partner to European and North American healthcare enterprises. Ultimately, ARCHIMED strives to build bigger and better healthcare businesses to deliver improved health outcomes and help people across the world.

After Big 4 in Europe and in the US, Merger & Acquisition and CFO experiences in US/European public and private companies, White Star Consulting provides customized services to companies in need of strategic financial leadership to achieve their business goals. Assist clients to design, implement and manage the right financial strategy to deliver value creation. Acting as interim/fractional CFO.

Pioneering Pancreatic Cancer Care Through First-in-Class Discovery Engine. Value Proposition:Groundbreaking Science to target Pancreatic Cancer through Complementary Mechanisms

The acceleration fund for Tech and Healthcare organisations with global ambitions

Turn French innovative healthcare organisations into world leaders

Biolog-id develops value-chain optimization solutions that create, collect, and consolidates high quality data to drive operational, commercial, and clinical impact for high-value high-impact health products. Biolog-id’s patented platform is used by multiple customers in the US, Europe, Middle East, India, and Asia Pacific.Recently, I directed end-to-end finance management, implemented financial strategies, strengthened business finance, raised capital, and oversaw cross-functional teams / departments, including procurement, legal, IT, IP, and compliance. My key contributions included…- Member of EXCOM and Board of Directors; leveraged skills across venture capital, private equity, and Software as a Service (SaaS).- Enabled IPO/SPAC readiness and met regulatory requirements by implementing governance, financial reporting, and internal processes. - Passed Historical IFRS Financials audits through maintaining accuracy in financial statements and consistency in accounting policies. - Prepared for US IPO/SPAC by leading organization, corporate, governance, and strategic sourcing activities.

About Cellectis: Cellectis is a biopharmaceutical company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). The company’s mission is to develop a new generation of cancer therapies based on engineered T-cells. Using its life-science-focused, pioneering genome-engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets. Cellectis S.A. is listed on the Nasdaq Global Market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). Calyxt, Inc., its US plant sciences subsidiary, shows promising developments and commenced field trials of cold storable potatoes in the United States of America and high oleic/low transfat soybean varieties in Argentina and the United States of America.About my position:Managed 20 direct reports and 15 indirect reports across USA and France to facilitate finance, budgeting, internal control / SOX, tax, and procurement practices. Excelled as member of EXCOM, Audit Committee, and Board of Directors to influence business and finance decisions by leveraging key skills across corporate financial planning and analysis. Coordinated with IT and supply chain departments to share and obtain key financial information.● $300M fundraisings by conducting investor meetings and managing investor relations. ● Functioned as transformation lead for key initiatives, that accounted for business stability. ● Led and completed special projects such as takeover defense, SAP improvements, NetSuite / Tagetik / Concur implementations, and IT roadmap.● Acted as CFO of Calyxt (Nasdaq: CLXT), subsidiary of Cellectis; Set up supply chain and commercial back-office, enabled 110M$ capital raise following Nasdaq IPO, managed products portfolio, and led special projects as M&A and Business model definition.

Championed two strategic projects: development of adjacent business in energy in China for Air Liquide and market analysis and business model proposal in Poland for Thales.

I was in charge of leading financial due diligence on behalf of various groups, supporting valuation of target companies and identification of growth drivers. I facilitated business executives by offering financial advisory across monthly reporting, budgets / business plans, cash forecasts, purchase / sale agreements, and business valuation. My key contributions included… - Conducted 100+ financial due diligence (acquisitions and disposals) for local / foreign corporate and private equity firms across various sectors. - 70% successful transaction rate for all projects. - Succeeded to lead diversified, multi-site, multicultural, and multi-project teams of up to 30 people.

Led audit of accounts prepared under USGAAP/IFRS in accordance with SOX rules along with enabling $200M adjustment by conducting analysis of accounting treatment of stock options for Computer Associates group.

Audited consolidated financial statements of Vivendi Universal with over 1K subsidiaries and in IFRS/USGAAP. Set up and led internal control assessment procedures for Veolia with over 2.5K subsidiaries under framework of SOX Act in US.

Offered finance and audit support and executed special missions for management of Charbonnages de France.